- Home
- AACB vs PHAT Comparison
AACB vs PHAT Comparison
Compare AACB & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACB
- PHAT
- Stock Information
- Founded
- AACB 2024
- PHAT 2018
- Country
- AACB United States
- PHAT United States
- Employees
- AACB N/A
- PHAT N/A
- Industry
- AACB
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- AACB
- PHAT Health Care
- Exchange
- AACB Nasdaq
- PHAT Nasdaq
- Market Cap
- AACB 276.2M
- PHAT 289.0M
- IPO Year
- AACB 2025
- PHAT 2019
- Fundamental
- Price
- AACB $9.98
- PHAT $3.14
- Analyst Decision
- AACB
- PHAT Strong Buy
- Analyst Count
- AACB 0
- PHAT 5
- Target Price
- AACB N/A
- PHAT $17.80
- AVG Volume (30 Days)
- AACB 6.7K
- PHAT 2.2M
- Earning Date
- AACB 01-01-0001
- PHAT 05-01-2025
- Dividend Yield
- AACB N/A
- PHAT N/A
- EPS Growth
- AACB N/A
- PHAT N/A
- EPS
- AACB N/A
- PHAT N/A
- Revenue
- AACB N/A
- PHAT $81,859,000.00
- Revenue This Year
- AACB N/A
- PHAT $201.74
- Revenue Next Year
- AACB N/A
- PHAT $114.16
- P/E Ratio
- AACB N/A
- PHAT N/A
- Revenue Growth
- AACB N/A
- PHAT 3055.70
- 52 Week Low
- AACB $9.90
- PHAT $2.35
- 52 Week High
- AACB $9.98
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- AACB N/A
- PHAT 40.55
- Support Level
- AACB N/A
- PHAT $2.21
- Resistance Level
- AACB N/A
- PHAT $4.45
- Average True Range (ATR)
- AACB 0.00
- PHAT 0.42
- MACD
- AACB 0.00
- PHAT -0.08
- Stochastic Oscillator
- AACB 0.00
- PHAT 41.52
About AACB Artius II Acquisition Inc. Class A Ordinary Shares
Artius II Acquisition Inc is a blank check company.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.